Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Brand Name :
halaven
Synonyms :
Class :
Anti-neoplastic, anti-microbial
Dosage Forms & Strengths
Intravenous solution:
1mg/2ml(0.5mg/ml)
IV: 1.4mg/m2 on days 1 to 8 of a 21-day cycle over 2-5 min
Liposarcoma metastatic:
IV: 1.4mg/m2 on days 1 to 8 of a 21-day cycle over 2-5 min
Dose Adjustments
Kidney impairment:
CrCl ≥50 mL/minute: No initial dosage adjustment is necessary
CrCl 15 to 49 mL/minute: Reduce initial dose to eribulin mesylate 1.1 mg/m2
Hepatic impairment:
Mild hepatic impairment: reduce initial dose to 1.1 mg/m2
Moderate hepatic impairment: reduce initial dose to 0.7 mg/m2
Severe hepatic impairment: No dosage adjustment provided in the US manufacturing list
Safety and efficacy not established
Refer adult dosing
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
QTc interval is increased both by lenvatinib and eribulin
when both drugs are combined, both increase the QTC interval
both lapatinib and eribulin increase the QTc interval
eribulin and gilteritinib, when used in combination, increase the QTc interval
When eribulin is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When eribulin is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
It may enhance the risk of adverse reactions when combined with Enzymes
Frequency defined:
>10%
Neutropenia (82%)
Anemia (58%)
Asthenia/fatigue (54%)
Alopecia (45%)
Peripheral neuropathy (35%)
Nausea (35%)
Constipation (25%)
Arthralgia/myalgia (22%)
Pyrexia (21%)
Weight loss (21%)
Anorexia (20%)
Headache (19%)
Vomiting (18%)
Diarrhea (18%)
Back pain (16%)
Dyspnea (16%)
Cough (14%)
Bone pain (12%)
Extremity pain (11%)
Urinary tract infection (10%)
1-10%
Increased lacrimation
Dyspepsia
Abdominal pain
Stomatitis
Xerostomia
URI
Hypokalemia
Muscle spasm/weakness
Dysgeusia
Dizziness
Insomnia
Depression
Rash
Post-marketing reports:
Pancreatitis
Lymphopenia
Hepatotoxicity
Drug hypersensitivity
Pneumonia
Pruritus
Stevens-Johnson syndrome
No contraindications listed in the US manufacturing label
Pregnancy consideration: The drug may cause fetal harm when administered
Pregnancy category: D
Lactation: The release of the drug in human breast milk is unknown
Pregnancy category:
Patient information leaflet
Generic Name:eribulin
Pronounced: [e-RIB-ue-lin]
Why do we use eribulin?
Eribulin is used to treat metastatic breast cancer in patients.